Summit Therapeutics stock plunges after FDA rejects lung cancer drug
Summit Therapeutics' stock fell 19% after the FDA rejected its lung cancer drug, ivonescimab, due to insufficient overall survival benefits in a late-stage trial. The drug delayed disease progression but did not meet the primary endpoint. Summit plans to continue discussions with the FDA, citing updated data showing survival improvements.
How this was made
The 30-second read
Why it matters
The FDA's denial underscores the challenge of demonstrating overall survival benefit, a key hurdle for oncology approvals.
Market read
Regulatory denial drives immediate sell‑off; sector peers may experience heightened scrutiny.
What to watch
Potential for the company to pursue alternative regulatory pathways or partner deals to mitigate impact.
Background
Summit Therapeutics acquired ivonescimab rights from Akeso in 2022; the drug targets PD‑1 and VEGF pathways.
Ticker impact
FDA issued a complete response letter rejecting Summit Therapeutics' lung cancer drug ivonescimab, causing a 19% pre‑market drop.
likely pressure as the market prices in the FDA rejection and lack of overall survival benefit.
The FDA denial is a primary, material regulatory event for a biotech; traders typically sell on such news.
Market effects
May weigh on other oncology biotech stocks awaiting FDA decisions.
US biotech sector could see modest pullback in early trading.
Limited to markets with exposure to US biotech equities.
Counterpoint
If updated survival data later convinces the FDA, a rebound could occur, but short‑term risk remains high.
Key entities
- CompanySummit Therapeutics
US‑listed biotech developing ivonescimab.
- RegulatorFDA
U.S. Food and Drug Administration issuing the CRL.




